Results 1 to 10 of about 19,369 (169)

Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation: a case series and literature review [PDF]

Frontiers in Oncology
BackgroundThe neurofibromin 1 (NF1) protein regulates the downstream RAS/RAF/MEK/ERK pathway and functions as a tumor suppressor. Somatic pathogenic mutations in NF1 are found in approximately 4.7%–10% of NSCLC, with a higher frequency in lung ...
Floryane Kim, Maxime Borgeaud, Maxime Borgeaud, Claudio De Vito, Petros Tsantoulis, Petros Tsantoulis, Alfredo Addeo   +6 more
doaj   +2 more sources

Trametinib Inhibits the Growth and Aerobic Glycolysis of Glioma Cells by Targeting the PKM2/c-Myc Axis

Frontiers in Pharmacology, 2021
Gliomas are primary tumors originating from glial progenitor cells. Traditional treatments, including surgery, radiotherapy, and chemotherapy, have many limitations concerning the prognosis of patients with gliomas.
Mingjun Gao, Mingjun Gao, Mingjun Gao, Jin Yang, Jin Yang, Jin Yang, Hailong Gong, Hailong Gong, Hailong Gong, Yuancai Lin, Yuancai Lin, Yuancai Lin, Jing Liu, Jing Liu, Jing Liu   +14 more
doaj   +1 more source

Trametinib activates endogenous neurogenesis and recovers neuropathology in a model of Alzheimer’s disease

Experimental and Molecular Medicine, 2023
Enhancing adult neurogenesis in the brain has been suggested as a potential therapeutic strategy for AD. We developed a screening platform, ATRIVIEW®, for molecules that activate neuronal differentiation of adult mouse NSCs.
Mi-Yeon Kim, Mi Jeong Kim, Changyeob Lee, Juwon Lee, Sang Seong Kim, Sungho Hong, Hyoung Tae Kim, Jinsoo Seo, Ki-Jun Yoon, Sungho Han   +9 more
doaj   +1 more source

Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer

Molecular Oncology, 2023
Blocking the mitogen‐activated protein kinase (MAPK) pathway with the MEK1/2 inhibitor trametinib has produced promising results in patients with head and neck squamous cell carcinoma (HNSCC).
Ofra Novoplansky, Avital B. Shnerb, Divyasree Marripati, Sankar Jagadeeshan, Raghda Abu Shareb, Cristina Conde‐López, Jonathan Zorea, Manu Prasad, Talal Ben Lulu, Ksenia M. Yegodayev, Chen Benafsha, Yushi Li, Dexin Kong, Fengshen Kuo, Luc G. T. Morris, Ina Kurth, Jochen Hess, Moshe Elkabets   +17 more
doaj   +1 more source

The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation

Transplantation Direct, 2020
Background. Potential adverse effects, such as functional impairment of islets, render conventional immunosuppressive drugs unsuitable for use in islet transplantation. In addition, as a single therapy, they cannot prolong islet allograft survival. Here,
Seiichiro Tada, MD, Takayuki Anazawa, MD, PhD, Takero Shindo, MD, PhD, Kei Yamane, MD, Kenta Inoguchi, MD, Nanae Fujimoto, MSc, Kazuyuki Nagai, MD, PhD, Toshihiko Masui, MD, PhD, Hideaki Okajima, MD, PhD, Kyoichi Takaori, MD, PhD, Shoichiro Sumi, MD, PhD, Shinji Uemoto, MD, PhD   +11 more
doaj   +1 more source

Cross-species analysis of SHH medulloblastoma models reveals significant inhibitory effects of trametinib on tumor progression

Cell Death Discovery, 2023
Sonic Hedgehog (SHH) medulloblastomas (MBs) exhibit an intermediate prognosis and extensive intertumoral heterogeneity. While SHH pathway antagonists are effective in post-pubertal patients, younger patients exhibit significant side effects, and tumors ...
Stephanie Borlase, Alexandria DeCarlo, Ludivine Coudière-Morrison, Lisa Liang, Christopher J. Porter, Vijay Ramaswamy, Tamra E. Werbowetski-Ogilvie   +6 more
doaj   +1 more source

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia

Фармакоэкономика, 2023
Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib combination in the first-line therapy for metastatic or unresectable BRAF V600-mutated melanoma in the Russian Federation. Material and methods.
N. A. Avxentyev, Yu. V. Makarova
doaj   +1 more source

Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report

Thoracic Cancer, 2023
Dabrafenib plus trametinib is the standard treatment for BRAF V600E‐mutated non‐small cell lung cancer. No treatment‐related cerebral infarction (CI) has been reported in previous clinical trials.
Yoshihiko Taniguchi, Akihiro Tamiya, Atsushi Yanagisawa, Minako Shimaya, Mayu Kawakami, Yuji Inagaki, Nobuhiko Saijo, Yoshinobu Matsuda, Kyoichi Okishio   +8 more
doaj   +1 more source

Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib

Cancer Biology & Therapy, 2022
In this study, we report a differential response of mitogen-activated protein kinase–kinase (MEK) inhibitor trametinib in 20 head and neck squamous cell carcinoma (HNSCC) patients’ tumor-derived cell cultures.
Myles Vigoda, Chase Mathieson, Nathaniel Evans, Carolyn Hale, Jennifer Jennings, Olivia Lucero, Sophia Jeng, Daniel Bottomly, Daniel Clayburgh, Peter Andersen, Ryan Li, Daniel Petrisor, Jeffrey W. Tyner, Shannon McWeeney, Molly Kulesz-Martin   +14 more
doaj   +1 more source

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Biomedicines, 2021
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC).
Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno   +10 more
doaj   +1 more source